Heres why this cheap blue-chip pharma stock is a solid buy for dividend, value, and growth investors alike....…
In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.38, marking a +1.42% move from the previous day....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Preclinical Data Supports Expanded Therapeutic Index and Provides Rationale for Ongoing Clinical Studies Preclinical Data Supports Expanded Therapeutic Index and…
Neither drugmaker has been a winner this year. But one appears to be a pretty safe bet to win in…
This healthcare stock could be a gamechanger for long-term investors who buy in today....…
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb...…
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, NextEra Energy, Goldman Sachs and Illumina...…
Top Research Reports for Netflix, Bristol-Myers & NextEra...…
Bristol-Myers Squibb (BMY) closed at $56.95 in the latest trading session, marking a -0.19% move from the prior day....…
Zacks.com featured highlights include: Big Lots, Dollar General, Kroger and Bristol-Myers...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol-Myers (BMY) is well positioned to outperform the market, as it exhibits above-average growth in financials....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol-Myers (BMY) gets FDA nod for Opdivo for the treatment of esophageal squamous cell carcinoma....…
Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers Opdivo as first-line maintenance treatment for…
Bristol-Myers Squibb (BMY) closed at $60.16 in the latest trading session, marking a -1.26% move from the prior day....…
The partnership will assess the safety, tolerability, and preliminary efficacy of UbiVacs investigational product DRibble Platform Vaccine 001(DPV-001) in combination…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol-Myers (BMY) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $60.89, marking a +1.13% move from the previous day....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Which of these household names is the better buy?...…
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…
True North met both primary endpoints, demonstrating highly statistically significant (p-value < 0.0001) results for induction of clinical remission at…
Zacks.com featured highlights include: Keurig Dr Pepper, Bristol-Myers Squib, Vistra Energy, IHS Markit and Campbell Soup...…
Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…
Shares of Bristol-Myers Squibb Inc. gained 1.2% in premarket trading on Tuesday after the drugmaker said Zeposia met both…
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol-Myers Squibb (BMY) closed at $59.72 in the latest trading session, marking a -0.15% move from the prior day....…
Bristol-Myers (BMY) possesses solid growth attributes, which could help it handily outperform the market....…
Bristol-Myers (BMY) gets EC nod for Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis....…
With the EC marketing authorization, Zeposia, an oral medication taken once daily, becomes the only approved sphingosine-1-phosphate (S1P) receptor modulator…
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, Fidelity National Information Services, Alibaba and Bristol-Myers Squibb...…
Bristol-Myers Squibbs stock (NYSE: BMY) has significantly outperformed the broader markets as well as some of its peers over the…
Zacks.com featured highlights include: Taiwan Semiconductor Manufacturing Company, Dollar General, Kroger, Bristol-Myers Squibb and NIC...…
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy…
Which stock wins in a battle between these two big drugmakers?...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
The U.S. Food and Drug Administration on
Friday approved Bristol Myers Squibb Cos combination
therapy for previously untreated patients with a form…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…